Here's What Wall Street Thinks About Haleon plc (HLN)

​Haleon plc (NYSE:HLN) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 8, David Hayes from Jefferies maintained a Buy rating on Haleon plc (NYSE:HLN) with a price target of p440.

The analyst noted several factors which are expected to improve the company’s performance, including easier sale comparisons in Latin America, positive impact of innovation in Europe and other emerging markets, along with stabilization in the North America. As a result, the analyst forecasts the company’s organic sales to grow at 3.4% during FQ3 2025 and raised his forecast to 3.6% growth in FQ4. He remains optimistic in ​Haleon plc’s (NYSE:HLN) growth potential and expects the company to accelerate growth in 2026.

In addition to Jefferies, on October 10, Barclays analyst Warren Ackerman maintained a Hold rating on Haleon plc (NYSE:HLN) with a price target of p380.

​Haleon plc (NYSE:HLN) is a consumer healthcare company offering a wide range of products across six major categories, such as oral health, vitamins, pain relief, respiratory, digestive, and skin health.

While we acknowledge the potential of HLN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.